2025-09-28 - Analysis Report
Okay, here's an analysis of Tempus AI (TEM) based on the data you provided, presented with numerical summaries and then a brief analysis.

## TEM (Unknown Company) Analysis - September 27, 2025

**Company Overview:** Tempus AI is an unknown company in the precision oncology sector.

### 1. Performance vs. S&P 500 (VOO)

*   **TEM Cumulative Return:** 43.50%
*   **VOO Cumulative Return:** 19.77%
*   **Absolute Divergence (Current):** 18.4%
*   **Relative Divergence:** 45.3% (meaning TEM's outperformance is in the 45.3 percentile of its historical range).
*   **Divergence Range (Max/Min):** 73.8% / -27.4%

**Alpha, Beta Analysis Table**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2023-2025  | 44.0% | 74.1% | 24.0% | 0.0 | 13.6 |

**Analysis:** TEM has significantly outperformed the S&P 500, but its relative divergence suggests this outperformance, while positive, is not at its extreme.  The Alpha of 24% indicates the stock has generated returns above what would be expected based on market movements alone, while Beta of 0 suggests TEM's price is not correlated with the overall market, which is unusual. High MDD (74.1%) suggests high volatility.

### 2. Recent Price Action

*   **Current Price:** \$78.48
*   **Previous Close:** \$77.33
*   **Change:** 1.49% (Positive Change)
*   **5-Day Moving Average:** \$80.39
*   **20-Day Moving Average:** \$81.91
*   **60-Day Moving Average:** \$70.02

**Analysis:** The stock is trading below its 5-day and 20-day moving averages but above its 60-day moving average.  The 1.49% positive change suggests a recent upward movement.

### 3. Market Risk Indicators

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 47.46 (Neutral)
*   **PPO:** -1.87 (Below Zero - Potential Oversold)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (12 shares - Very Safe - MRI:0.90) Monthly invest 5.9% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-09-02)
*   **20-Day Relative Divergence Change:** -11.1 (Negative - Short-term Decrease in Relative Performance)
*   **Expected Return (%):** NaN

**Analysis:**

*   The MRI indicates a high investment recommendation.
*   The RSI is neutral, suggesting neither overbought nor oversold conditions.
*   The PPO indicates the stock may be approaching an oversold state.
*   The negative change in relative divergence suggests recent underperformance compared to VOO, despite the long-term outperformance.
*   Given the recent positive price change and the negative short term Relative Divergence, one can see the stock has experienced a small recovery.
*   "Expected Return" is unavailable, indicating either insufficient data or high uncertainty in projecting future outperformance.

### 4. Recent News & Significant Events

*   **Key Themes:** FDA clearances for various diagnostic tools and platforms (xR IVD, cardiac imaging platform, Pixel's radiology portfolio).  Analyst discussions about TEM vs. ILMN.

**Analysis:** The news is overwhelmingly positive, highlighting FDA approvals and a generally positive outlook on growth.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (Mean: 2.15)
*   **Number of Opinions:** 11
*   **Target Price:**
    *   Average: \$74.82
    *   High: \$98.00
    *   Low: \$60.00

**Analysis:** Analyst consensus is positive, with a "Buy" rating.  The average target price is slightly below the current price, while a high target price is significantly higher.

### 5. Recent Earnings Analysis

| 날짜         | EPS   | 예상 EPS |
|--------------|-------|----------|
| 2025-08-08 | -0.22 | -0.22988 |
| 2025-05-06 | -0.24 | -0.26003 |
| 2025-02-24 | -0.18 | -0.15    |
| 2024-11-04 | -0.25 | -0.26608 |
| 2024-08-06 | -0.63 | -0.59    |

**Analysis:** TEM consistently reports negative EPS. However, recent results have generally exceeded expectations.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | \$0.31B | 61.99%        |
| 2025-03-31 | \$0.26B | 60.69%        |
| 2024-12-31 | \$0.20B | 60.83%        |
| 2024-09-30 | \$0.18B | 58.50%        |
| 2024-06-30 | \$0.17B | 45.50%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE        |
|------------|---------|------------|
| 2025-06-30 | \$0.31B | -13.84%    |
| 2025-03-31 | \$0.33B | -20.86%    |
| 2024-12-31 | \$0.06B | -23.10%    |
| 2024-09-30 | \$0.05B | -141.16%   |
| 2024-06-30 | \$0.10B | -562.04%   |

**Analysis:**

*   Revenue is growing steadily.
*   Profit margins are very high and stable, indicating strong pricing power.
*   ROE is negative, reflecting ongoing losses, but has improved recently.

### 7. 종합 Analysis

**Summary:**

TEM is a high-growth company in the precision oncology sector, demonstrating strong revenue growth and high profit margins. It has significantly outperformed the S&P 500, although recent relative performance has dipped slightly. The company is still loss-making (negative EPS and ROE), but is generally beating EPS expectations. Recent FDA approvals are a major positive catalyst. Analyst consensus is a "Buy," although the average target price is close to the current price, suggesting limited immediate upside. The MRI indicates a favorable environment, and considering its high growth potential, it has the potential to provide high investment.

**Key Considerations:**

*   **Valuation:** While growth is strong, the company is not yet profitable.
*   **Volatility:** The stock has exhibited high volatility in the past.
*   **Reliance on FDA approvals:** Future growth is significantly dependent on further regulatory approvals.
